It's not too late to join the rally in KALA PHARMA, but not yet
As earnings approach
KALA
is taking a very bullish trajectory and seemingly some positioning is taking place. Currently the 200 &100 day MA's are converging and will hopefully avoid a bearish cross , if the price can break above we believe it to a good entry point.
AVERAGE ANALYSTS PRICE TARGET $19.57
AVERAGE ANALYSTS RECOMMENDATION buy
P/E RATIO
SHORT INTEREST 7%
COMPANY PROFILE
Kala Pharmaceuticals, Inc. is a biopharmaceutical company, focused on the development and commercialization of therapeutics using proprietary nanoparticle-based Mucus Penetrating Particles, or MPP, technology, with an initial focus on the treatment of eye diseases. The company was founded by Justin Hanes, Robert S. Langer and Colin R. Gardner in 2009 and is headquartered in Waltham, MA.
KALA
is taking a very bullish trajectory and seemingly some positioning is taking place. Currently the 200 &100 day MA's are converging and will hopefully avoid a bearish cross , if the price can break above we believe it to a good entry point. AVERAGE ANALYSTS PRICE TARGET $19.57
AVERAGE ANALYSTS RECOMMENDATION buy
P/E RATIO
SHORT INTEREST 7%
COMPANY PROFILE
Kala Pharmaceuticals, Inc. is a biopharmaceutical company, focused on the development and commercialization of therapeutics using proprietary nanoparticle-based Mucus Penetrating Particles, or MPP, technology, with an initial focus on the treatment of eye diseases. The company was founded by Justin Hanes, Robert S. Langer and Colin R. Gardner in 2009 and is headquartered in Waltham, MA.